No TB drug lawsuits, J&J promises

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

No TB drug lawsuits, J&J promises

Markham, Ontario, Canada - May 21, 2018: Johnson & Johnson Medical Products company in Markham, Ontario, a division of  Johnson & Johnson Inc.

Johnson & Johnson won’t enforce patents for bedaquiline after months of public scrutiny and new licences for generics

Activists have hailed a “sea change” in the treatment of tuberculosis after Johnson & Johnson agreed not to enforce patents covering bedaquiline on Friday, September 29.

J&J said the decision was intended to reassure generics makers that they could market cheaper versions of bedaquiline, a TB drug, in 134 low- and middle-income countries.

In July, the company granted licences for the drug to the UN-backed Stop TB Partnership’s Global Drug Facility.

J&J has faced significant pressure from activists and civil society groups this year over its patent portfolio on bedaquiline.

Bestselling author John Green was among those to lend his voice to a campaign calling on J&J to halt its efforts to secure additional patents on bedaquiline, with the core intellectual property rights set to expire this year.

In March, India’s IP office refused J&J’s application for a secondary patent on bedaquiline after a challenge brought by two TB survivors.

Last month, meanwhile, South Africa’s Competition Commission launched an investigation after it emerged the country wouldn’t benefit from lower prices for the drug worldwide.

Prices for bedaquiline fell sharply after July’s deal with the Global Drug Facility.

J&J now charges most lower-income countries a headline price of $130 for a six-month course of the drug, but South Africa will continue to pay the old figure of $289.

A J&J spokesperson said the company would cooperate fully with the investigation.

Christophe Perrin, TB advocacy pharmacist at Médecins Sans Frontières’s Access Campaign, said the decision announced on Friday, September 29, was “testament to the persistent efforts of TB activists, civil society, and also countries prioritising public health over corporations' interests”.

Perrin called on Japanese drugmaker Otsuka, which owns patents for the drug delamanid, to match J&J’s pledge not to enforce its IP.

Delamanid is often used in combination with bedaquiline to treat multidrug-resistant TB.

“We need all newer TB innovations to be as affordable as absolutely possible, so governments can scale up prevention, testing and treatment to beat back this curable disease that continues to kill 1.6 million people every year.

“People with TB literally cannot afford to wait any longer,” Perrin said.

more from across site and SHARED ros bottom lb

More from across our site

A $110 million US verdict against Apple and an appellate order staying a $39 million trademark infringement finding against Amazon were also among the top talking points
Attorneys are watching how AI affects trademark registrations and whether a SCOTUS ruling from last year will have broader free speech implications
Patent lawyers explain why they will be keeping an eye on the implications of a pharma case and on changes at the USPTO in the second half of 2025
The insensitive reaction to a UK politician crying on TV proves we have a long way to go before we can say we are tackling workplace wellbeing
Adrian Percer says he was impressed by the firm’s work on billion-dollar cases as well as its culture
In our latest interview with women IP leaders, Catherine Bonner at Murgitroyd discusses technology, training, and teaching
Developments included an update in the VAR dispute between Ballinno and UEFA, the latest CMS updates, and a swathe of market moves
The LMG Life Sciences Americas Awards is thrilled to present the 2025 shortlist
A new order has brought the total security awarded to a Canadian tech company to $45 million, the highest-ever by an Indian court in an IP case
Andrew Blattman reflects on how IP practices have changed and shares his hopes for increased AI use and better performance on the stock market
Gift this article